| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/ARCHNEUR.61.5.673 |
| P698 | PubMed publication ID | 15148143 |
| P2093 | author name string | Diego F Wyszynski | |
| Ellice Lieberman | |||
| Lewis B Holmes | |||
| P433 | issue | 5 | |
| P304 | page(s) | 673-678 | |
| P577 | publication date | 2004-05-01 | |
| P1433 | published in | Archives of Neurology | Q15766672 |
| P1476 | title | The AED (antiepileptic drug) pregnancy registry: a 6-year experience | |
| P478 | volume | 61 |
| Q28304952 | Adult epilepsy |
| Q34213596 | Anatomical and behavioral effects of in utero exposure to antiepileptic drugs |
| Q36998327 | Antiepileptic drug exposure and major congenital malformations: the role of pregnancy registries |
| Q35153696 | Antiepileptic drug use by pregnant women enrolled in Florida Medicaid |
| Q37341158 | Antiepileptic drug use in women of childbearing age. |
| Q36527829 | Antiepileptic drugs and neurodevelopment |
| Q55716842 | Antiepileptic drugs and pregnancy outcomes. |
| Q34905287 | Antiepileptic drugs during pregnancy: what is known and which AEDs seem to be safest? |
| Q33949402 | Antiepileptic drugs in women with epilepsy during pregnancy |
| Q36623339 | Are newer antiepileptic drugs associated with improved safety in pregnancy compared to older antiepileptic drugs? |
| Q34999895 | Assessment of congenital anomalies in infants born to pregnant women enrolled in clinical trials |
| Q36292532 | Birth defects after prenatal exposure to antiepileptic drugs |
| Q30870008 | Birth defects data from population-based birth defects surveillance programs in the United States, 2007 to 2011: highlighting orofacial clefts. |
| Q45156781 | Can we ensure the safe use of known human teratogens? Introduction of generic isotretinoin in the US as an example |
| Q35894122 | Challenges in Studying Modifiable Risk Factors for Birth Defects |
| Q33861432 | Comparative safety of anti-epileptic drugs among infants and children exposed in utero or during breastfeeding: protocol for a systematic review and network meta-analysis |
| Q36697463 | Currently available antiepileptic drugs |
| Q34623867 | Do the results of pregnancy registries contradict one another? |
| Q33926194 | Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry |
| Q37029076 | Effects of in utero antiepileptic drug exposure |
| Q28199588 | Ensuring the safe and effective use of medications during pregnancy: planning and prevention through preconception care |
| Q81431773 | Epilepsy in pregnancy |
| Q37044837 | Ethical and regulatory issues related to pregnancy registries and their outcomes |
| Q33837161 | Ethics review of studies during public health emergencies - the experience of the WHO ethics review committee during the Ebola virus disease epidemic |
| Q37299848 | Exposure to Excess Phenobarbital Negatively Influences the Osteogenesis of Chick Embryos |
| Q37419974 | Gender-specific psychosocial impact of living with epilepsy |
| Q34555052 | In utero antiepileptic drug exposure: fetal death and malformations |
| Q36745801 | In utero exposure to antiepileptic drugs: teratogenicity and neonatal morbidity |
| Q36142531 | Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register |
| Q34722379 | Management of epilepsy during pregnancy |
| Q36476623 | Management of epilepsy in women of childbearing age: practical recommendations |
| Q36166299 | Migraine during pregnancy: options for therapy |
| Q84143031 | No increase in adverse pregnancy outcomes for women receiving antiepileptic drugs |
| Q37345485 | Obstetric and birth outcomes in pregnant women with epilepsy: A hospital-based study |
| Q24198152 | Preconception counselling for women with epilepsy to reduce adverse pregnancy outcome |
| Q24242734 | Preconception counselling for women with epilepsy to reduce adverse pregnancy outcome |
| Q24244559 | Preconception counselling for women with epilepsy to reduce adverse pregnancy outcome |
| Q37404526 | Pregnancy and epilepsy: what should we tell our patients? |
| Q46622852 | Pregnancy and epilepsy:update on pregnancy registries |
| Q37138858 | Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts |
| Q33377652 | Pregnancy registries: strengths, weaknesses, and bias interpretation of pregnancy registry data |
| Q37203417 | Pregnancy registries: what do they mean to clinical practice? |
| Q61849018 | Preschool behavioral problems in children prenatally exposed to antiepileptic drugs — A follow-up study |
| Q34098311 | Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009. |
| Q84581302 | Teratogenic effects of antiepileptic drugs |
| Q34267151 | Teratogenic effects of antiepileptic drugs |
| Q37301544 | Teratogenicity and antiepileptic drugs: potential mechanisms |
| Q42954735 | Teratogenicity of antiepileptic drugs |
| Q37262946 | Teratogenicity of antiepileptic medications |
| Q36577270 | Therapy insight: clinical management of pregnant women with epilepsy |
| Q43581122 | Undue regulatory control on phenobarbital--an important yet overlooked reason for the epilepsy treatment gap. |
| Q33899323 | Using current evidence in selecting antiepileptic drugs for use during pregnancy |
| Q33941242 | Valproate poses risk to unborn child |
| Q36384705 | Valproic acid in epilepsy : pregnancy-related issues |
| Q36896245 | Women with epilepsy: hormonal issues from menarche through menopause. |
| Q52933504 | [EURAP: the European Registry of Antiepileptic Drugs and Pregnancy]. |
| Q80606154 | [Treatment of epilepsy in adults. Options and strategies] |
Search more.